PRIMARY STUDY
Engineered Lactobacillus paracasei Producing Palmitoylethanolamide (PEA) Prevents Colitis in Mice
Key Findings: Administration of palmitoylethanolamide (PEA) to mice in this model of ulcerative colitis (UC) found a significant reduction in inflammatory markers and cellular damage suggesting potential therapeutic use of PEA in the treatment of inflammatory bowel and intestinal disease, as in UC.
Type of Study: Animal Study
Study Sample Size: 70
Study Result: Positive
Research Location(s): China, Italy
Year of Pub: 2021
Cannabinoids Studied: Palmitoylethanolamide (PEA)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2, PPAR - Alpha, PPAR - Gamma
Ligands Studied: Pro-inflammatory cytokines
Route of Administration: Oral (Ingestion)
Citation: Esposito G, et al. Engineered Lactobacillus paracasei Producing Palmitoylethanolamide (PEA) Prevents Colitis in Mice. Int J Mol Sci. 2021; 22:(unknown pages). doi: 10.3390/ijms22062945
Authors: Esposito G, Pesce M, Seguella L, Lu J, Corpetti C, Del Re A, De Palma FDE, Esposito G, Sanseverino W, Sarnelli G
